Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s260. https://doi.org/10.25251/skin.7.supp.260